Can You Mix Semaglutide and Mounjaro — and Should You?

The decision in front of you: same goal, different mechanisms

The reason this question comes up so often is that semaglutide and tirzepatide (the active ingredient in Mounjaro) look, on the surface, like they do roughly the same thing. Both reduce appetite, slow gastric emptying and help people lose weight. The difference is the receptor count. Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. That second pathway is the pharmacological distinction that makes tirzepatide the only dual-agonist weight-loss medicine currently licensed in the UK, and it also explains why people sometimes ask whether Mounjaro is actually semaglutide, given how similarly the two treatments are often described.

If you are trying to decide which one to start, or whether switching makes sense after a plateau, that is a legitimate clinical question. If you are wondering whether taking both at once could be more effective, the answer is no, the pathways overlap too much, the GI side-effect burden compounds, and there is no trial evidence supporting dual-agent use. The NHS medicines guidance for both tirzepatide and semaglutide is clear that these are individual, standalone treatments. So the real decision is: which one is right for you?

You can read a fuller breakdown of how the two treatments sit alongside each other on our Wegovy vs Mounjaro comparison page.

What the evidence shows when you compare them directly

Head-to-head data now exists. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, ran tirzepatide against semaglutide 2.4mg in adults with obesity over 72 weeks. Tirzepatide produced greater average weight loss. SURMOUNT-1, which enrolled thousands of adults without diabetes, reported average body-weight reductions of around 20–21% at the highest tirzepatide dose; STEP 1, the equivalent semaglutide trial, reported around 15% at 2.4mg. NICE appraised both and recommends tirzepatide under TA1026.

That does not make tirzepatide the right answer for every person. Tolerability, existing conditions, other medicines you take and practical factors all feed into the choice. Some people do better on semaglutide; some find the titration schedule suits them; some have a medical reason that favours one over the other. It is also worth knowing that significant weight loss on either medicine can lead to changes in facial appearance, something our page on Mounjaro, tirzepatide and facial fat loss covers in detail. The table below sets out the key factual differences.

For a closer look at how the cost picture differs between the two, our price comparison page sets that out plainly.

Switching between them: what that actually involves

A more common real-world scenario than combining them is switching, moving from semaglutide to tirzepatide, or the other way, usually because results have plateaued or tolerability is an issue. This is clinically possible, but it requires proper assessment. There is no direct dose-conversion table that maps one medicine onto the other; a prescriber reviews your current dose, your response, any ongoing side effects, and sets an appropriate starting point for the new medicine. You do not simply carry on where you left off.

Our prescribers handle switch assessments as part of the consultation process. If you are transferring from another provider, you will need to provide evidence of your current treatment and dose history, which is standard practice at a regulated service. You can find out more about how the consultation works on our treatment page, or read about the clinical team who oversee assessments on the clinical team profile.

One thing worth flagging: if you have seen people online asking about running both medicines simultaneously, our dedicated pages on mixing tirzepatide and semaglutide and on mixing Mounjaro and Wegovy explain in full why that is not a route any registered UK prescriber should be offering. If a seller is suggesting combined use (or is willing to supply either medicine without a clinical assessment) treat that as a red flag. The MHRA has warned repeatedly about illegitimate online sellers of weight-loss injectables. Report anything suspicious via the MHRA Yellow Card scheme.

Which medicine suits you best is a clinical decision our prescribers make with you, based on your health history and goals. Speak to our prescribers through a free consultation to work out the right path forward.